Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-24
2006-01-24
McKenzie, Thomas C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000, C514S051000
Reexamination Certificate
active
06989376
ABSTRACT:
Methods of treating certain neurological diseases using exogenous uridine or a uridine source alone as a precursor of endogenous cytidine, particularly in the human brain, are disclosed. Methods are also disclosed wherein exogenous uridine or a uridine source is combined either with drugs increasing uridine availability or with compounds that serve as a source of choline in phospholipid synthesis.
REFERENCES:
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5141943 (1992-08-01), Naguib et al.
patent: 5470838 (1995-11-01), von Borstel et al.
patent: 5567689 (1996-10-01), Sommadossi et al.
patent: 5583117 (1996-12-01), von Borstel et al.
patent: 5723449 (1998-03-01), Sommadossi et al.
patent: 5962459 (1999-10-01), Piazza et al.
patent: 6472378 (2002-10-01), von Borstel et al.
patent: 2003/0114415 (2003-06-01), Wurtman et al.
patent: 0178267 (1986-04-01), None
patent: 0178267 (1986-04-01), None
patent: 07/215879 (1995-08-01), None
patent: 7215879 (1995-08-01), None
patent: 09/30976 (1997-02-01), None
patent: 2001/233776 (2001-08-01), None
patent: 2001/233776 (2004-08-01), None
patent: 2003332 (1993-11-01), None
patent: WO 89/03837 (1989-05-01), None
patent: 8903837 (1989-05-01), None
patent: WO89/03837 (1989-05-01), None
patent: 9743899 (1997-11-01), None
patent: WO 97/43899 (1997-11-01), None
patent: WO97/43899 (1997-11-01), None
patent: WO97/45127 (1997-12-01), None
patent: 9745127 (1997-12-01), None
patent: WO 97/45127 (1997-12-01), None
patent: WO 00/50043 (2000-08-01), None
patent: WO00/50043 (2000-08-01), None
Page et al., “Developmental Disorder Associated with Increased Cellular Nucleotidase Activity,”Proc. National Academy of Sciences USA, 94(21), 11601-11606 (Oct. 14, 1997).
Coirault et al., “Uridine 5-Triphosphate in Therapy. I. Cure of Neurogenic Muscular Atrophy,”La Presse Medicale(Fr.),68(29), 1127-1129 (Jun. 11, 1960);Chemical Abstracts, 57(7), p. 73, Abstract No. 10485f (Oct. 1, 1962).
Merlini et al., “Effects of Large Doses of Pyrimidine Nucleosides Cytidine and Uridine in Elderly Patients with Neuropsychological Disturbances Caused by Vascular and Cerebral Metabolic Insufficiency,”Gazzetta Medica Italiana Archivio Scienze Mediche, 145(6), 379-390 (Jun., 1966);Biological Abtracts, 83, Abstract No. 27367 (1987).
Gallai et al. (I), “Effects of Uridine in the Treatment of Diabetic Neuropathy: An Electrophysiological Study,”Acta Neurol. Scand., 86(1), 3-7 (1992);Biological Abtracts, 94, Abstract No. 112030 (1992).
Gallai et al. (II), “Multi-Infarct Dementia: Modification of the P300 Cognitive Event-Related Potential in Patients Treated with the Association of Cytidine and Uridine,”Rivista di Neuropsichiatria e Science Affini, 41(1), 1-9 (1995);BIOSIS, 1996, Abstract Citation No. 466219; only Abstract supplied.
Drago et al., “Memory Deficits of Aged Male Rats Can Be Improved by Pyrimidine Nucleosides and N-Acetylglutamine,”Clinical Neuropharmacology, 13(4), 290-296 (1990);Biological Abstracts, 90, Abstract No. 91117 (1990).
Manna et al., “Effects of Short-Term Administration of Cytidine, Uridine and L-Glutamine Alone or in Combination on the Cerebral Electrical Activity of Patients with Chronic Cerebrovascular Disease,”Intl. Journal Clinical Pharmacology Research, 8(3), 199-210 (1988);Biological Abstracts, 86, Abstract No. 51989 (1988).
Keilbaugh et al., “Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2′, 3′-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal Model, by Uridine and Pyruvate,”Molecular Pharmacology, 44(4), 702-706 (Oct. 1, 1993);BIOSIS, 1994, Abstract Citation No. 413648.
Popov et al., “Protective Effect of Uridine on D-Galactosamine-Induced Deficiency in Brain Uridine Phosphates,”Biomedica Biochimica Acta, 43(12), 1399-1404 (1984);Biological Abstracts, 80, Abstract No. 34525 (1985).
Ingraham et al., “Nucleoside Diphosphokinase fromSalmonella typhimurium,” Chapter 48 inMethods in Enzymology, LI(vol. 51), Hoffee et al. (eds.), New York, NY, 1978, Academic Press, only pp. 371 and 375 supplied; assorted portions of other chapters were also supplied including pp. 305, 306, 318, 327, 329 and 330.
Miyazaki et al., “Effects of Nucleotides on Learning and Memory in a Morris Water Maze Test in Normal and Basal Forebrain-Lesioned Rats,”Life Sciences, 64(1), 45-52 (Nov. 27, 1998).
Entingh et al., “Brain Uridine Monophosphate: Reduced Incorporation of Uridine During Avoidance Learning,”Brain Research, 70(1), 131-138 (Apr. 12, 1974); only abstract supplied.
Rüthrich et al., “Increase of Guanosine Incorporation into RNA of Hippocampal Neurons by Application of Uridine Monophosphate During a Learning Experiments,”Brain Research, 69(1), 49-55 (Mar. 29, 1974); only abstract supplied.
Ott et al. (I), “Effects of RNA Precursors on Development and Maintenance of Long-Term Memory,”Psychopharmacologia, 28(2),195-204(1973);Chemical Abstracts, 78(19), p. 77, Abstr. No. 119731q, (May 14, 1973).
Ott et al. (II), “Influence of 6-Azauridine on Facilitation of Relearning by Precursors of Ribonucleic Acid,”Psychopharmacologia, 23(3),272-278(1972);Chemical Abstracts, 76(25), p. 103, Abstr. No. 149588z, (Jun. 19, 1972).
A. Lehninger,Biochemistry, Second Edition, Worth Publishers, Inc., New York, NY, Jul., 1978, only pp. 735-737 supplied.
Gibbons et al.,Biochemistry of Cholesterol, Elsevier Biomedical Press, New York , NY, 1982, only pp. 258 and 259 supplied.
Lodish et al.,Molecular Cell Biology, W. H. Freeman & Co., New York, NY, 2000, only pp. 68-78 supplied, see especially pp. 75-76.
Zaffaroni et al., “Adrenal Conversion of C14Labeled Cholesterol and Acetate to Adrenal Cortical Hormones,”Journal of the American Chemical Society, 73, 1390-1391 (Mar., 1951).
Kato et al., “Determinants of Sex Hormone Levels in Men as Useful Indices in Hormone-Related Disorders,”Journal of Clinical Epidemiology, 45(12), 1417-1421 (Dec., 1992).
(YA) Gibbons et al., Biochemistry of Cholesterol, Elsevier Biomedical Press, New York, NY, 1982, only pp. 258 and 259 supplied.
(ZA) Lodish et al., Molecular Cell Biology, W. H. Freeman & Co., New York, NY, 2000, only pp. 68-78 supplied, see especially pp. 75-76.
(RB) Zaffaroni et al., “Adrenal Conversion of C14 Labeled Cholesterol and Acetate to Adrenal Cortical Hormones,” Journal of the American Chemical Society, 73, 1390-1391 (Mar., 1951).
(SB) Kato et al., “Determinants of Sex Hormone Levels in Men as Useful Indices in Hormone-Related Disorders,” Journal of Clinical Epidemiology, 45(12), 1417-1421 (Dec., 1992).
|R| Page et al., “Developmental Disorder Associated with Increased Cellular Nucleotidase Activity,” Proc. National Academy of Sciences USA, 94(21), 11601-11606 (Oct. 14, 1997).
(S) Coirault et al., “Uridine 5-Triphosphate in Therapy. I. Cure of Neurogenic Muscular Atrophy,” La Presse Medicale(Fr.), 68(29), 1127-1129 (Jun. 11, 1960); Chemical Abstracts, 57(7), p. 73, Abstract No. 10485f (Oct. 1, 1962).
(T) Merlini et al., “Effects of Large Doses of Pyrimidine Nucleosides Cytidine and Uridine in Elderly Patients with Neuropsychological Disturbances Caused by Vascular and Cerebral Metabolic Insufficiency,” Gazzetta Medica Italiana Archivio Scienze Medic.
(U) Gallai et al. (I), “Effects of Uridine in the Treatment of Diabetic Neuropathy: An Electrophysiological Study,” Acta Neurol. Scand., 86(1), 3-7 (1992); Biological Abtracts, 94, Abstract No. 112030 (1992).
(V) Gallai et al. (II), “Multi-Infarct Dementia: Modification of the P300 Cognitive Event-Related Potential in Patients Treated with the Association of Cytidine and Uridine,” Rivista di Neuropsichiatria e Science Affini, 41(1), 1-9 (1995); BIOSIS, 1996, Ab.
(W) Drago et al., “Memory Deficits of Aged Male Rats Can Be Improved by Pyrimidine Nucleosides and N-Acetylglutamine,” Clinical
Watkins Carol
Wurtman Richard J.
Cohen Mark
Crane L. E.
Massachusetts Institute of Technology
Pearl Cohen Zedek Latzer LLP
LandOfFree
Methods for increasing blood cytidine and/or uridine levels... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for increasing blood cytidine and/or uridine levels..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for increasing blood cytidine and/or uridine levels... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3534911